Disease-specific survival following the brachytherapy management of prostate cancer
- 1 March 2006
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 64 (3) , 810-816
- https://doi.org/10.1016/j.ijrobp.2005.09.005
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- 12-YEAR OUTCOMES FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 2005
- PROSTATE SPECIFIC ANTIGEN DOUBLING TIME AS A SURROGATE END POINT FOR PROSTATE CANCER SPECIFIC MORTALITY FOLLOWING RADICAL PROSTATECTOMY OR RADIATION THERAPYJournal of Urology, 2004
- Combined modality treatment in the management of high-risk prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantationInternational Journal of Radiation Oncology*Biology*Physics, 2002
- PROSTATE BRACHYTHERAPY: TREATMENT STRATEGIESJournal of Urology, 1999
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999
- A Dose–Response Study for I-125 Prostate ImplantsInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: Implications for patient selection in the radiotherapeutic management of prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1995
- A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantationInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling timeInternational Journal of Radiation Oncology*Biology*Physics, 1993